489 related articles for article (PubMed ID: 35662189)
21. Ferritinophagy and α-Synuclein: Pharmacological Targeting of Autophagy to Restore Iron Regulation in Parkinson's Disease.
Boag MK; Roberts A; Uversky VN; Ma L; Richardson DR; Pountney DL
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216492
[TBL] [Abstract][Full Text] [Related]
22. Alpha-synuclein, lipids and Parkinson's disease.
Ruipérez V; Darios F; Davletov B
Prog Lipid Res; 2010 Oct; 49(4):420-8. PubMed ID: 20580911
[TBL] [Abstract][Full Text] [Related]
23. Experimental Parkinson models and green chemistry approach.
Akyazı O; Korkmaz D; Cevher SC
Behav Brain Res; 2024 Jun; 471():115092. PubMed ID: 38844056
[TBL] [Abstract][Full Text] [Related]
24. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
25. Metals, oxidative stress and neurodegenerative disorders.
Jomova K; Vondrakova D; Lawson M; Valko M
Mol Cell Biochem; 2010 Dec; 345(1-2):91-104. PubMed ID: 20730621
[TBL] [Abstract][Full Text] [Related]
26. Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities.
Orad RI; Shiner T
J Neurol; 2022 Feb; 269(2):639-653. PubMed ID: 33511432
[TBL] [Abstract][Full Text] [Related]
27. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
28. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias.
Colloby SJ; McParland S; O'Brien JT; Attems J
Brain; 2012 Sep; 135(Pt 9):2798-808. PubMed ID: 22961551
[TBL] [Abstract][Full Text] [Related]
29. Alpha-Synuclein Aggregation in Parkinson's Disease.
Srinivasan E; Chandrasekhar G; Chandrasekar P; Anbarasu K; Vickram AS; Karunakaran R; Rajasekaran R; Srikumar PS
Front Med (Lausanne); 2021; 8():736978. PubMed ID: 34733860
[TBL] [Abstract][Full Text] [Related]
30. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
Cinar E; Yalcin-Cakmakli G; Saka E; Ulusoy A; Yuruker S; Elibol B; Tel BC
Exp Neurol; 2020 Aug; 330():113357. PubMed ID: 32437708
[TBL] [Abstract][Full Text] [Related]
31. Proteomic approach to studying Parkinson's disease.
Zhang J; Goodlett DR
Mol Neurobiol; 2004 Jun; 29(3):271-88. PubMed ID: 15181239
[TBL] [Abstract][Full Text] [Related]
32. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
33. [The role of aluminum and lead in the development of Alzheimer's and Parkinson's diseases].
Salkov VN; Khudoerkov RM
Arkh Patol; 2021; 83(3):56-61. PubMed ID: 34041898
[TBL] [Abstract][Full Text] [Related]
34. Examining the Toxicity of α-Synuclein in Neurodegenerative Disorders.
Shan FY; Fung KM; Zieneldien T; Kim J; Cao C; Huang JH
Life (Basel); 2021 Oct; 11(11):. PubMed ID: 34833002
[TBL] [Abstract][Full Text] [Related]
35. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
[TBL] [Abstract][Full Text] [Related]
37. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
38. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
[TBL] [Abstract][Full Text] [Related]
39. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders.
Norris EH; Giasson BI
Antioxid Redox Signal; 2005; 7(5-6):672-84. PubMed ID: 15890012
[TBL] [Abstract][Full Text] [Related]
40. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
